
Ansa Biotechnologies has closed a $71.5 million oversubscribed Series C financing, bringing our total funding to $211 million. Read the full press release at ansabio.bio/4zvUsAV

Enabling the next generation of DNA synthesis using enzymes. You can also find us at @ansabio.bsky.social

Ansa Biotechnologies has closed a $71.5 million oversubscribed Series C financing, bringing our total funding to $211 million. Read the full press release at ansabio.bio/4zvUsAV

Ansa Biotechnologies thanks all who have served in the US armed forces.

Download our eBook, DNA Synthesis for the AI Era. This comprehensive guide explores how enzymatic DNA synthesis is changing reliability, sequence complexity, and speed. #DNASynthesis #EnzymaticDNASynthesis #AI ansabio.bio/4BznYYR

We're hiring for multiple open roles! View the job postings: ansabio.bio/4zxJpIw!

Whole Plasmid Synthesis is now in Early Access. Submit your plasmid map, we write the whole construct. Unlike other providers, we synthesize from scratch, so no physical DNA is needed. You define the construct: ansabio.bio/4A9Alt8

What makes a DNA sequence hard to synthesize? Two constructs of identical length can take very different paths through a manufacturing workflow. Read the DNA Synthesis 101 blog: #DNASynthesis #DNASynthesis101 ansabio.bio/4A7agLb

Announcing Early Access orders for Whole Plasmid Synthesis at Ansa. We synthesize, assemble, and verify your full plasmid, including complex GC-rich and repetitive sequences. See the full details and get started with Early Access: ansabio.bio/4A19OOC


The Ansa Team celebrated Oktoberfest! A special thanks to Matthias Arenskötter for the homemade German food. The spread included bratwurst, Leberkäse, spaetzle, sauerkraut, red cabbage, pretzels, and fresh bread, plus vegan sausages. #Oktoberfest #TeamEvent #Bratwurst #Spaetzle

Meet with the Ansa team at ESGCT, October 27-30, 2026, and see how our DNA synthesis platform can support your gene and cell therapy research. 📍 Find us at Booth C-08 at the Congress Center Hamburg. Schedule time: ansabio.bio/4i0kLsg

Daniel Lin-Arlow noticed that DNA writing had barely changed in a decade, so he helped build a company to fix it. ansabio.bio/4BkURZh

Great conversations at ELRIG Drug Discovery this week where we presented a poster in collaboration with Axio Biopharma. Missed us at the meeting? Download the poster: ansabio.bio/4yyMKG4

More DNA. Less bench work. Announcing DNA SCALE-UP, a new product add-on for Clonal DNA and XL Clonal DNA orders. Get consistent, high-purity DNA from the same verified clone, w/o re-culturing & re-prepping. 🧪hubs.li/Q04z9DX60

Avoid dead-end workflows when your fragment request hits a limit. With IDT and @AnsaBio, there’s a better path forward. ⏩ Our “No Loose Ends” workflow helps guide complex designs beyond fragment fit—toward fully assembled clonal genes, without losing momentum. 🧬 So when your project gets more ambitious, your workflow doesn’t stall. Learn more here: idtb.io/07t7jr

𝗔𝘁𝘁𝗲𝗻𝗱𝗶𝗻𝗴 𝗔𝗦𝗛𝗚 𝟮𝟬𝟮𝟲 𝗶𝗻 𝗠𝗼𝗻𝘁𝗿𝗲𝗮𝗹? 𝗟𝗲𝘁’𝘀 𝗰𝗼𝗻𝗻𝗲𝗰𝘁! 🧬 Schedule time to meet with the Ansa team and explore how our enzymatic DNA synthesis platform can help advance your research. 👉Schedule time to meet: ansabio.bio/4jjb9eN

Two biosecurity wins! CA enacted gene synthesis screening requirements, and Ansa joined the International Gene Synthesis Consortium. ➡️ AB 1864: lnkd.in/ey7yA5Fs ➡️ IGSC: lnkd.in/g6ZxJJeh